Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with ImatinibLaura Cesini, Roberto Latagliata, Lorenzo Rizzo et al.|Oncology Research and Treatment|2019Cited by 9
Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?Roberto Latagliata, Robin Foà, Massimo Breccia et al.|European Journal Of Haematology|2018Cited by 6
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significanceSara Mohamed, Marco Mancini, Roberto Latagliata et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 2
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center CohortSofia Chiatamone Ranieri, Roberto Latagliata, Maria Antonietta Arleo et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 2
Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?Daniela De Benedittis, Roberto Latagliata, Massimo Breccia et al.|Blood|2018Cited by 0